Eutypoids B−E Produced by aPenicilliumsp. Strain from the North Sea by Schulz, Dirk et al.
Eutypoids B-E Produced by a Penicillium sp. Strain from the North Sea
Dirk Schulz,† Birgit Ohlendorf,† Heidi Zinecker,‡ Rolf Schmaljohann,† and Johannes F. Imhoff*,†
Kieler Wirkstoff-Zentrum (KiWiZ) at the Leibniz-Institute of Marine Sciences (IFM-GEOMAR), Am Kiel-Kanal 44, 24106 Kiel, Germany
ReceiVed September 8, 2010
Crude extracts of the Penicillium sp. strain KF620 isolated from the North Sea showed antimicrobial activities against
Xanthomonas campestris and Candida glabrata. Purification of the extracts led to the isolation of the new aromatic
butenolides eutypoids B (1), C (2), D (3), and E (4). Their structures were elucidated by NMR spectroscopy and supported
by HRESIMS and UV data. The antibacterial activity of the crude extracts was due to the presence of the known
diketopiperazine fellutanine (cyclo(Trp-Trp)). The eutypoids were neither cytotoxic nor antibacterial, but inhibited the
activity of glycogen synthase kinase-3.
Various strains of the genus Penicillium are known for their
ability to produce bioactive compounds.1,2 During our investigations
of marine fungi isolated from the North Sea, Penicillium sp. KF620
was selected for detailed study. This strain showed profound
antibacterial activity in combination with a diverse metabolite
spectrum. The metabolites were isolated and identified as the new
aromatic butenolides eutypoids B-E (1-4) as well as the known
diketopiperazine fellutanine (cyclo(Trp-Trp)).3 The only previously
reported phenyl- and benzyl-substituted butenolide natural products
without a substitution at C-5 and C-6 are eutypoid A4 and
gymnoascolide A.5
Penicillium sp. KF620 was grown in static culture and extracted
with EtOAc to give a crude extract. The extract was fractionated
by column chromatography on Sephadex LH-20 (MeOH) and
finally by preparative HPLC to yield compounds 1-4 as colorless
solids.
High-resolution ESIMS mass measurements of 1 (measured
305.0792, calculated 305.0784 [M + Na]+) gave the molecular
formula C17H14O4, which required 11 degrees of unsaturation and
was fully consistent with the spectroscopic data of eutypoid B. The
structure of 1 was established on the basis of one- and two-
dimensional NMR spectra (1H, 13C (1H decoupled and DEPT),
1H-1H COSY, 1H-13C HSQC, and 1H-13C HMBC). The 13C NMR
spectrum included four particularly intense signals accounting for
two magnetically equivalent carbons each, C-8 plus C-12 (δC 130.6
ppm), C-9 plus C-11 (δC 116.8 ppm), C-14 plus C-18 (δC 131.5
ppm), and C-15 plus C-17 (δC 116.4 ppm), indicating the presence
of two para-substituted aromatic rings. Two quaternary carbons with
the shifts δC 128.6 ppm (C-7) and 122.3 ppm (C-13), which
connected the aromatic rings to the rest of the molecule, and two
oxygen-bearing aromatic carbons, C-10 (δC 157.7 ppm) and C-16
(δC 159.1 ppm), were also detected. The 13C NMR spectrum
revealed the presence of an ester/lactone carbonyl group C-2 (δC
176.3), two methylene carbons C-5 (δC 72.8 ppm) and C-6 (δC
33.8 ppm), and two sp2-hybridized carbons C-3 (δC 127.2 ppm)
and C-4 (δC 162.4 ppm), consistent with a tetrasubstituted double
bond conjugated to the carbonyl function. The structural elements
already deduced from the 13C NMR spectrum could be confirmed
by the analysis of the 1H and the two-dimensional NMR spectra.
Thus, the equivalent aromatic methine protons H-8 plus H-12 (δH
6.99) and H-9 plus H-11 (δH 6.73) gave a doublet each due to
coupling with each other and showed 1H-13C HMBC correlations
to the quaternary carbons C-7 and C-10. The same pattern could
be observed for the second aromatic ring consisting of C-14 plus
C-18 (δH 7.35), C-15 plus C-17 (δH 6.87), and the quaternary
carbons C-13 and C-16. The para substitution of each aromatic ring
with a hydroxy group was obvious from the shifts of C-10 and
C-16. The second aromatic ring was directly bonded to the double
bond ∆3,4, while the first one was connected via C-6, which could
be proven by 1H-13C HMBC correlations from H2-6 (δH 3.87 ppm)
to C-8 plus C-12. Additionally, the signal of H2-6 coupled to C-13
from the second aromatic ring and all carbons belonging to the
R,-unsaturated γ-butyrolactone. The methylene group belonging
to the γ-butyrolactone ring, CH2-5 (δC 72.8, δH 4.71), had to be
located adjacent to an oxygen atom, as proven by its chemical shifts.
As the double bond, the ester carbonyl, and the two aromatic rings
accounted for only 10 degrees of unsaturation, the presence of a
lactone ring, which was already indicated by the chemical shifts,
was confirmed. Thus, the structure of eutypoid B (1) was estab-
lished.
1 and the three derivatives eutypoids C (2), D (3), and E (4)
could be shown to share the same R,-unsaturated γ-butyrolactone
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Figure 1. Selected 1H-13C HMBC correlations relevant for the
structure elucidation of 1.
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substructure substituted with different aromatic moieties. Their
structures, just as that of 1, were confirmed by the analysis of
different one- and two-dimensional NMR spectra. The substitution
patterns of the aromatic rings could be deduced from the 1H NMR
spectra. The high-resolution mass measurement of 2 (measured
321.0733, calculated 321.0733 [M + Na]+) and the resulting
molecular formula C17H14O5 indicated the substitution of the two
aromatic rings with three hydroxy groups. As in 1, H-14 plus H-18
(δΗ 7.35 ppm) and H-15 plus H-17 (δΗ 6.87 ppm) were shown to
be equivalent aromatic methines, which coupled with a coupling
constant of J ) 8.7, evidence of a para-substituted phenyl ring.
The other aromatic ring was substituted with two hydroxy groups
adjacent to each other, as shown by the signal splitting patterns of
the aromatic protons. H-12 showed 3J coupling (J ) 8.0) to H-11
and 4J coupling (J ) 2.1) to H-8, which proved the second aromatic
ring to be 1,2,4-substituted.
3 had the same molecular formula as 2 and also contained one
para-substituted aromatic ring. The signals of the remaining
aromatic protons of 3 were partly overlapping, but it was obvious
that all coupling constants were below 3 Hz, which proved that
none of them were neighboring protons. Therefore, the second
aromatic ring could only be 1,3,5-substituted.
4 showed a mass increase of 16 compared to 2 and 3, accounting
for one additional hydroxy group. From the signal splitting patterns
one 1,2,4- and one 1,3,5-substituted aromatic ring could be deduced.
The structures of all three derivatives were confirmed by analysis
of the two-dimensional NMR spectra.
The simplest structure of a butenolide would be 2-furanone,
which is a common substructure of natural products from various
sources including fungi and bacteria.6 Phenyl- and benzyl-
substituted butenolides have previously been described as fungal
metabolites. Related structures are gymnoascolides A-C produced
by Gymnoascus reessii,5 eutypoid A isolated from Eutypa sp.,4
microperfuranone reported from Anixiella micropertusa,7 and
9-hydroxymicroperfuranone described as a metabolite of Emericella
quadrilineata.8 The highly hydroxylated aromatic rings in combina-
tion with no substitution at C-5 and C-6 sets the new compounds
apart from the known metabolites.
1-4 were evaluated in several in Vitro enzyme assays including
glycogen synthase kinase-3 (GSK-3) as a target. The serine/
threonine protein kinase GSK-3 is involved in numerous signaling
pathways and has emerged as a key target for the treatment of
Alzheimer’s disease and type 2 diabetes.9
Eutypoids B-E show moderate inhibitory activities against the
enzyme GSK-3 with IC50 values in the low micromolar range.
Interestingly, the synthetic inhibitor of GSK-3 SB-415286 (3-(3-
chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-
dione), discovered in a chemical-synthesis screening approach,
shows some structural relationships with the eutypoids (Figure 2).10
Thus, high-throughput screening of synthetic compound libraries
and traditional natural product research can result in the discovery
of structurally similar compounds as inhibitors of the same target.
However, the eutypoids are approximately 30 times less active than
SB-415286 (Table 3).
Eutypoids B-E were inactive in cytotoxicity and antimicrobial
bioassays. No biological activity has been reported for eutypoid
A, gymnoascolides B/C, and microperfuranone and its hydroxide,
either, although gymnoascolide A is active against Septoria
nodorum.5 Eutypoids B-E were inactive against Septoria tritici.
Experimental Section
General Experimental Procedures. UV spectra were obtained on
a NanoVue photometer (GE Healthcare). NMR spectra were recorded
on a Bruker DRX500 spectrometer (500 and 125 MHz for 1H and 13C
NMR, respectively), using the signals of the residual solvent protons
and the solvent carbons as internal references (δH 3.31 and δC 49.0
ppm for methanol-d4). High-resolution mass spectra were acquired on
a benchtop time-of-flight spectrometer (MicrOTOF, Bruker Daltonics)
with positive electrospray ionization. Analytical reversed-phase HPLC-
UV/MS experiments were performed using a C18 column (Phenomenex
Onyx Monolithic C18, 100 × 3.00 mm) applying an H2O (A)/MeCN
(B) gradient with 0.1% HCOOH added to both solvents (gradient: 0
min 5% B, 4 min 60% B, 6 min 100% B; flow 2 mL/min) on a VWR
Hitachi Elite LaChrom system coupled to an ESI-ion trap detector
(Esquire 4000, Bruker Daltonics).
Preparative HPLC was carried out using a Merck Hitachi system
consisting of an L-7150 pump, an L-2200 autosampler, an L-2450 diode
array detector, and a Phenomenex Gemini C18 110A AXIA, 100 ×
21.20 mm, or a Phenomenex Luna silica 5 µm, 250 × 10.00 mm
column.
Microorganisms and Fermentation. Strain KF620 was isolated
from a water sample collected during a research cruise on the North
Sea. By morphological characteristics the fungus could be identified
as a member of the genus Penicillium. Sequence analysis of the 18S
rRNA gene and the internal spacer region (ITS-1) revealed 99%
similarity to P. Verrucosum, P. Viridicatum, P. allii, P. albocoremium,
P. neoechinulatum, P. hordei, and P. tricolor, but did not allow
identification on the species level.
For the production of secondary metabolites the fungus was
cultivated in 9 L of liquid saline (3% Tropic Marin sea salt, Dr. Biener
GmbH, Wartenberg, Germany) Wickerham medium11 (12 × 750 mL)
at 28 °C for 21 days in static cultures.
Isolation of Eutypoids B-E. A 9 L portion of a Penicillium sp.
KF620 culture was separated into culture filtrate and mycelium. The
culture filtrate was extracted with EtOAc. The organic extract was
concentrated in Vacuo to dryness to give a crude extract of 0.64 g. The
extract was fractionated by column chromatography on Sephadex LH-
20 (3 × 80 cm, MeOH). Compounds 1-4 eluted in one fraction and
fellutanine in an other. All fractions were purified by preparative HPLC
(Phenomenex Gemini C18 110A AXIA column; linear gradient: 0 min
20% MeCN, 15 min 50% MeCN; flow 15 mL/min; detection at 280
nm) to yield 35 mg of compound 1 (tR5.8 min), 110 mg of compound
4 (tR 7.6 min), a mixture of compound 2 and 3 (tR 9.3 min), and 29 mg
of fellutanine (tR 9.7 min). The mixture of compounds 2 and 3 was
further purified by preparative HPLC (Phenomenex Luna silica 5 µm,
linear gradient: 0 min 85% 2-propanol, 10 min 95% 2-propanol; flow
3 mL/min; detection at 280 nm) to yield 20 mg of compound 2 (tR 4.1
min) and 36 mg of compound 3 (tR 5.1 min).
Table 1. NMR Spectroscopic Data (500 MHz, methanol-d4) of
Eutypoid B (1)
position δC. mult. δH. (J in Hz) COSY HMBC
2 176.3, C
3 127.2, C
4 162.4, C
5 72.8, CH2 4.71, s 6 2, 3, 4, 6, 13, 14 + 18
6 33.8, CH2 3.87, s 5, 8 + 12 2, 3, 4, 5, 7, 8 + 12, 13
7 128.6, C
8 + 12 130.6, CH 6.99, d (8.6) 6, 9 + 11 6, 8 + 12, 9 + 11, 10
9 + 11 116.8, CH 6.73, d (8.6) 8 + 12 7, 10, 9 + 11
10 157.7, C
13 122.3, C
14 + 18 131.5, CH 7.35, d (8.8) 15 + 17 3, 14, 15 + 17, 16
15 + 17 116.4, CH 6.87, d (8.8) 14 + 18 13, 15 + 17, 16
16 159.1, C
Figure 2. Structures of SB-415286 and 2.
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Eutypoid B (1): colorless, amorphous solid; UV (MeOH) λmax (log
ε) 277 (4.05), 224 (4.23) nm; for 1D and 2D NMR data see Table 1;
HRESIMS m/z 305.0792 (calcd for C17H14NaO4, 305.0784).
Eutypoid C (2): colorless, amorphous solid; UV (MeOH) λmax (log
ε) 282 (3.91), 222 (4.20) nm; for 1D and 2D NMR data see Table
2-3 and SI; HRESIMS m/z 321.0733 (calcd for C17H14NaO5, 321.0733).
Eutypoid D (3): colorless, amorphous solid; UV (MeOH) λmax (log
ε) 282 (3.91), 222 (4.20) nm; for 1D and 2D NMR data see Table 2
and SI; HRESIMS m/z 321.0733 (calcd for C17H14NaO5, 321.0733).
Eutypoid E (4): colorless, amorphous solid; UV (MeOH) λmax (log
ε) 288 (3.94), 222 (4.25) nm; for 1D and 2D NMR data see Table 2
and SI; HRESIMS m/z 337.0680 (calcd for C17H14NaO6, 337.0683).
Antibacterial and Antifungal Assays. Antimicrobial assays were
performed using Bacillus subtilis (DSM 347), Erwinia amyloVora (DSM
50901), Escherichia coli K12 (DSM 498), Pseudomonas fluorescence
(NCIMB 10586), Propionibacterium acnes (DSM 1897), Pseudomonas
aeruginosa (DSM 50071), Pseudomonas syringae pv aptata (DSM
50252), Ralstonia solanacearum (DSM 9544), Staphylococcus epider-
midis (DSM 20044), Staphylococcus lentus (DSM 6672), Xanthomonas
campestris (DSM 2405), the yeast Candida glabrata (DSM 6425), and
the fungus Septoria tritici. The antimicrobial assays were performed
as recently described by Schneeman et al. (2010).12
Cytotoxic Assays. The sensitivity of the cell lines NIH-3T3, HepG2,
and HT-29 to the isolated compounds was evaluated by monitoring of
the metabolic activity using the CellTiter-Blue cell viability assay
(Promega, Mannheim, Germany). The cultivation of the cell lines and
the bioassays were performed as described by Schneeman et al.
(2010).12
GSK-3 Inhibition Assay. To measure the inhibitory effect of the
isolated compounds, they were tested in an in Vitro activity assay
adapted from a luminescent assay described by Baki et al. (2007).13
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Table 2. NMR Spectroscopic Data (500 MHz, methanol-d4) of the Eutypoids
eutypoid B (1) eutypoid C (2) eutypoid D (3) eutypoid E (4)
position δC. mult. δH. (J in Hz) δC. mult. δH. (J in Hz) δC. mult. δH. (J in Hz) δC. mult. δH. (J in Hz)
2 176.3, C 176.3, C 176.3, C 176.3, C
3 127.2, C 127.2, C 127.2, C 127.2, C
4 162.4, C 162.4, C 162.4, C 162.4, C
5 72.8, CH2 4.71, s 72.8, CH2 4.71, s 72.7, CH2 4.68, s 72.7, CH2 4.68, s
6 33.8, CH2 3.87, s 34.0, CH2 3.79, s 33.8, CH2 3.86, s 34.0, CH2 3.80, s
7 128.6, C 129.4, C 129.3, C 129.4, C
8 130.6, CH 6.99, d (8.6) 116.6, CH 6.59, d (2.1) 130.7, CH 6.99, d (8.5) 116.8, CH 6.59, d (2.1)
9 116.8, CH 6.73, d (8.6) 146.4, C 116.7, CH 6.73, d (8.5) 146.7, C
10 157.7, C 145.5, C 157.6, C 145.5, C
11 116.8, CH 6.73, d (8.6) 116.7, CH 6.71, d (8.0) 116.7, CH 6.73, d (8.5) 116.8, CH 6.71, d (8.0)
12 130.6, CH 6.99, d (8.6) 120.9, CH 6.49, dd (8.0, 2.1) 130.7, CH 6.99, d (8.5)a 120.9, CH 6.51, dd (8.0, 2.1)
13 122.3, C 122.0, C 127.2, C 127.2, C
14 131.5, CH 7.35, d (8.8) 131.4, CH 7.35, d (8.7) 117.2, CH 7.00, ma 117.2, CH 7.03, dd (1.0, 1.5)
15 116.4, CH 6.87, d (8.8) 116.4, CH 6.87, d (8.7) 146.4, C 146.4, C
16 159.1, C 159.0, C 122.0, CH 6.85, ma 122.0, CH 6.85, ma
17 116.4, CH 6.87, d (8.8) 116.4, CH 6.87, d (8.7) 147.1, C 147.1, C
18 131.5, CH 7.35, d (8.8) 131.4, CH 7.35, d (8.7) 116.8, CH 6.85, ma 116.3, CH 6.85, ma
a Signals are overlapping.
Table 3. GSK-3 Inhibitory Activity of the Eutypoids and
SB-415286
GSK-3 inhibition
IC50 [µM]
SB-415286 0.09 ((0.01)
eutypoid B 0.78 ((0.02)
eutypoid C 0.67 ((0.04)
eutypoid D 4.08 ((1.4)
eutypoid E 2.26 ((0.13)
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